Organization
University Hospital Regensburg
1 clinical trial
6 abstracts
Abstract
Zotiraciclib for newly diagnosed or recurrent glioblastoma: Updated outcome and biomarker analysis.Org: University Hospital Zurich, Brain Tumor Centre, University of Zurich, EORTC Headquarters, Institute of Neuropathology,
Clinical trial
Randomized Phase II Trial With Safety run-in Phase Evaluating Low-dose AZA, ATRA and Pioglitazone Versus Standard Dose Azacitidine in Patients >=60 Years With AML Who Are Refractory to Standard Induction ChemotherapyStatus: Terminated, Estimated PCD: 2020-03-25
Abstract
Safety and efficacy of tumor treating fields (TTFields) prior and concomitant to radiotherapy in patients with newly diagnosed glioblastoma: Results from PriCoTTF.Org: University Medicine Essen - Ruhrlandklinik, University Duisburg-Essen, University Hospital Regensburg, Medical Center - University of Freiburg, Carl Gustav Carus University Hospital Dresden,
Abstract
Long-term survival with IDH wildtype glioblastoma: First results from the ETERNITY Brain Tumor Funders’ Collaborative Consortium (EORTC 1419).Org: University Hospital and University of Zurich, Institute of Neuropathology, University Hospital Düsseldorf, University of California, San Francisco, Division of Endocrinology, San Francisco, CA, University and City of Health and Science Hospital,
Abstract
CLDN6 CAR-T cell therapy of relapsed/refractory solid tumors ± a CLDN6-encoding mRNA vaccine: Dose escalation data from the BNT211-01 phase 1 trial using an automated product.Org: Friedrich-Alexander University Erlangen-Nuremberg, Netherlands Cancer Institute, Hannover Medical School, University Hospital Hamburg Eppendorf, University Medical Center Mainz,
Abstract
Prophylactic cerebral irradiation or active brain magnetic resonance imaging surveillance in small-cell lung cancer patients (EORTC-1901: PRIMALung).Org: Gustave Roussy Département d'Organisation du Parcours Patient, Jules Bordet Institute, Hôpitaux Universitaires de Bruxelles, Université Libre de Bruxelles (ULB), Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China,
Abstract
Breaking primary checkpoint inhibitor resistance: Interim analysis of a multicenter phase II study by intermittent application of an alkylating agent among patients with metastatic melanoma.Org: Department of Dermatology, Ludwig-Maximilians-Universität München, University Hospital Regensburg, University Hospital Würzburg, Universitätsklinikum Erlangen,